XHKG
0546
Market cap1.54bUSD
Jul 10, Last price
4.78HKD
1D
-0.83%
1Q
-30.72%
Jan 2017
25.46%
IPO
68.31%
Name
Fufeng Group Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fufeng Group Limited, an investment holding company, specializes in the global production and distribution of fermentation-based food additives, biochemicals, and starch-derived products, operating across markets in the People's Republic of China and internationally. Its business is structured into several key segments: Food Additives, Animal Nutrition, High-End Amino Acid, Colloid, and an encompassing 'Other' segment. The Food Additives division is responsible for manufacturing and selling items such as monosodium glutamate (MSG), starch sweeteners, glutamic acid, compound seasonings, and corn oil. The Animal Nutrition segment focuses on producing and selling refined corn products, threonine, and lysine. High-end amino acids are offered through its dedicated segment, while the Colloid segment provides specialty gums like xanthan and gellan gum. The 'Other' segment encompasses a diverse range of products, including fertilizers, synthetic ammonia, and pharmaceuticals. Beyond these core activities, Fufeng Group is also engaged in the manufacturing and sale of construction materials such as autoclaved aerated concrete blocks and bricks, alongside eubacteria material medicine and various preparations. The company actively invests in the research, development, promotion, and industrialization of innovative biological techniques and their resultant achievements. Furthermore, it deals in cosmetics, biological products, and health foods, while also offering logistics, equity investment, and biological technique information services. Fufeng Group Limited was founded in 1999 and is headquartered in Linyi, People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||